Project ID：DT-202500428-041
Product Brief Summary
- Product Name: Once daily oral brain-penetrant dual JAK1 x TYK2 inhibitor with better efficacy and safety
- Target: JAK1 x TYK2
- Modality: Small Molecule
- Therapeutic Area: Parkinson’s disease (PD)
- Current Stage: IND enabling
- Rights Available: China/Global Right
- Collaboration Mode: License out / co-development
More highlights
- Excellent safety profile: No CYP / hERG / mini-Ames issue.
- More potent than BHV-8000 (12X) and Upadacitinib (3X) in cellular assay
- Desirable Selectivity: > 40 folds JAK1 over JAK2
- Favorable brain penetration and longer lasting exposure than BHV-8000
- Ameliorates the symptoms and neuroinflammation in both rat & mouse models of Parkinson’s disease (PD) at lower dose than BHV-8000
- IND filing scheduled in Q4 2025
Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
发布者：qi.yang，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
